Tvorogova 1998.

Methods	no washout period required because no patient was receiving hypolipidaemic treatment within 3 months of trial entry 1‐month dietary stabilisation period 3‐month before and after trial
Participants	61 patients with primary hyperlipoproteinaemia, CAD with stable angina class II and III Total cholesterol > 6.5 mmol/L (250 mg/dL) LDL‐C > 4.3 mmol/L (165 mg/dL) 36 patients mean age of 45.9 years received simvastatin 25 patients mean age of 47.2 years received fluvastatin exclusion criteria: diabetes, nephrotic syndrome, chronic renal failure, liver disease, hypothyroidism, congestive heart failure, obesity grade II and III, worsening of diseases of the gastrointestinal tract Fluvastatin 20 mg/day baseline TC : 10.52 mmol/L (407 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 7.92 mmol/L (306 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.27 mmol/L (49 mg/dL) Fluvastatin 20 mg/day baseline triglycerides: 2.5 mmol/L (221 mg/dL)
Interventions	Fluvastatin 20 mg/day Simvastatin 10 mg /day
Outcomes	per cent change from baseline at 3 months of blood TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	Simvastatin 10 mg /day group was not included in the efficacy analysis SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported